Nephrology · Medical Literature
Calciphylaxis in chronic kidney disease: a systematic review of pathomechanisms and risk factors for calcific uremic arteriolopathy.
Abstract
Calcific uremic arteriolopathy (CUA) is a rare, severe condition affecting patients with chronic kidney disease (CKD). The etiology of CUA is unclear. Here, we aimed to identify factors associated with its development. We reviewed the existing evidence on its pathomechanisms and risk factors. We searched EMBASE and PubMed up to February 2026, reviewing all studies that would facilitate a comparison of CKD patients with and without CUA. Of 2374 screened publications, 35 met our inclusion criteria. The factors that consistently emerged related to CUA were decreased albumin, higher alkaline phosphatase, diabetes, increased body mass index, female sex, vitamin K antagonist (VKA) use, increased calcium phosphate product, and calcification and thrombosis in subcutaneous small arteries. Factors that appeared to be likely associated with CUA were anemia, suboptimal dialysis efficiency, peritoneal dialysis, inflammation, arterial hypertension, smoking, and hepatobiliary disease. Findings on matrix Gla protein alterations implicated in mediating VKA effects, parathyroid hormone, and hypercoagulability were ambiguous in our literature analyses. In addition, we found that a standardized system for CUA skin biopsy evaluation is lacking. In summary, our review delineates the major risk factors and pathogenic parameters associated with CUA development. Furthermore, it underscores areas in which robust data on CUA pathomechanisms are lacking.
Clinical relevance
Among patients with chronic kidney disease (CKD), what pathomechanisms and clinical or biochemical risk factors are consistently associated with the development of calcific uremic arteriolopathy (CUA/calciphylaxis)? __SNAPSHOT__ {"studyDesign":"Systematic review (without meta-analysis); comparative studies of CKD patients with versus without CUA","setting":"Not reported (multi-database literature search: EMBASE and PubMed, up to February 2026)","sampleSize":"35 studies included from 2,374 screened publications; individual patient numbers not reported in abstract","population":"Patients with chronic kidney disease (CKD) with and without calcific uremic arteriolopathy (CUA); subgroups including dialysis-dependent and non-dialysis CKD patients","intervention":"Exposure: presence of CUA (calciphylaxis); systematic synthesis of pathomechanisms and risk factors across comparative studies","comparator":"CKD patients without CUA","primaryOutcome":"Identification of factors (biochemical, clinical, histopathological) associated with development of CUA versus no CUA in CKD patients","followUp":"Not reported (systematic review of existing literature; follow-up duration of individual included studies not specified in abstract)","fundingSource":"Not reported"}
Key findings
Of 2,374 screened publications, 35 met inclusion criteria. The systematic review identified two tiers of evidence for CUA-associated factors. Factors that 'consistently emerged' as associated with CUA were: hypoalbuminemia, elevated alkaline phosphatase, diabetes mellitus, elevated body mass index (obesity), female sex, vitamin K antagonist (VKA) use, elevated calcium-phosphate product, and histopathological findings of calcification and thrombosis in subcutaneous small arteries. A second tier of factors judged 'likely associated' with CUA included anemia, suboptimal dialysis efficiency, peritoneal dialysis modality (versus hemodialysis), systemic inflammation, arterial hypertension, smoking, and hepatobiliary disease. Findings regarding matrix Gla protein (MGP) alterations — proposed as the mechanistic mediator of VKA-related CUA risk — parathyroid hormone (PTH) levels, and hypercoagulability were described as 'ambiguous' across the included literature. No pooled effect sizes, odds ratios, risk ratios, confidence intervals, or p-values are reported in the abstract. NNT/NNH cannot be calculated from available data. The abstract also notes that a standardized diagnostic/reporting system was identified as a need, though the full text of this finding was truncated in the provided abstract.
Practice implications
This systematic review synthesizes the best available comparative evidence on CUA risk factors in CKD, providing a clinically useful hierarchy of associations. The consistently identified risk factors — VKA use, hypoalbuminemia, elevated alkaline phosphatase, diabetes, obesity, female sex, and elevated calcium-phosphate product — align with and reinforce previously published risk factor profiles, lending reasonable confidence to these associations for clinical risk stratification. However, caution is essential: systematic reviews of observational data establish association, not causation. The ambiguity surrounding PTH, hypercoagulability, and MGP alterations underscores that widely cited mechanistic hypotheses remain insufficiently validated. The inclusion of peritoneal dialysis as a 'likely associated' modality and hepatobiliary disease as a risk factor represent clinically relevant but less-established signals that warrant awareness. Patients who are on warfarin (VKA), obese, diabetic, female, hypoalbuminemic, or have elevated alkaline phosphatase or calcium-phosphate product should be considered at heightened CUA risk, particularly if on dialysis. Critically, this is an abstract-only summary; the full text may contain additional methodological details, subgroup analyses, individual study quality assessments, and the truncated findings regarding standardization that are not accessible here, which limits the completeness of interpretation. The findings apply primarily to CKD populations studied in comparative designs; applicability to pre-dialysis CKD stages or non-CKD calciphylaxis is not defined by this review. __LIMITATIONS__ 1. Abstract-only access: the full text, including PRISMA flow, individual study quality ratings, risk of bias assessments, and complete findings, was not available for review. 2. Qualitative synthesis without meta-analysis: no pooled quantitative effect estimates, confidence intervals, or p-values are reported, limiting the ability to assess the magnitude of individual risk associations. 3. Underlying study heterogeneity: the 35 included studies likely vary substantially in design (case-control, cohort, registry), sample size, CKD stage, dialysis modality, outcome definitions, and covariate adjustment, which may not be adequately addressed without full-text review. 4. Selection and ascertainment bias: CUA is rare and often underdiagnosed; included comparative studies may overrepresent referral centers or biopsy-confirmed cases, limiting generalizability. 5. Confounding: many identified risk factors (e.g., diabetes, obesity, VKA use, malnutrition) co-occur and may be interrelated; confounding adjustment across individual studies is unlikely to be uniform. 6. Causality cannot be established: the systematic review design and its constituent observational studies do not permit causal inference for any identified association. 7. Ambiguous biomarkers: PTH, MGP, and hypercoagulability — pathomechanistically plausible factors — showed inconsistent signals, suggesting either true heterogeneity or methodological inconsistency across studies. 8. Generalizability: populations, diagnostic criteria for CUA, and definitions of risk factors likely varied across included studies, limiting universal applicability. 9. Funding source not reported, precluding assessment of potential sponsorship bias. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This systematic review of 35 comparative studies identifies hypoalbuminemia, elevated alkaline phosphatase, diabetes, obesity, female sex, VKA use, elevated calcium-phosphate product, and subcutaneous small-artery calcification/thrombosis as the most consistently supported risk factors for CUA in CKD patients. Clinicians should maintain a high index of suspicion for CUA in patients carrying multiple these features — particularly those on warfarin — and consider early specialist referral, as CUA carries a 1-year mortality exceeding 50%. However, because this is a qualitative synthesis without pooled effect estimates, and because key mechanistic hypotheses (PTH, MGP, hypercoagulability) remain ambiguous, these findings should primarily inform clinical risk awareness and hypothesis generation rather than definitively change management algorithms pending prospective validation.